Selenized liposomes with ameliorative stability that achieve sustained release of emodin but fail in bioavailability

Zhu, Mujuan; Zhu, Shiping; Liu, Qiubo; Ren, Yuehong; Ma, Zhiguo; Zhang, Qizhou

doi:10.1016/j.cclet.2022.04.080

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous report, an attempt to fortify the structural stability of liposomes by selenization was made. 64 Unfortunately, the modified liposomes with Se depositing onto the interior and exterior bilayers did not substantially facilitate absorption of model drug, though a reinforced structure of liposomes was established.…”

Section: Optimizing Oral Bioavailability With Vesiclesmentioning

confidence: 99%

Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement

Ren¹,

Nie²,

Zhu³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

Bioavailability is an eternal topic that cannot be circumvented by peroral drug delivery. Adequate blood drug exposure after oral administration is a prerequisite for effective treatment. Nanovesicles as pleiotropic oral vehicles can solubilize, encapsulate, stabilize an active ingredient and promote the payload absorption via various mechanisms. Vesicular systems with nanoscale size, such as liposomes, niosomes and polymersomes, provide a versatile platform for oral delivery of drugs with distinct nature. The amphiphilicity of vesicles in structure allows hydrophilic and lipophilic molecule(s) either or both to be loaded, being encapsulated in the aqueous cavity or the inner core, respectively. Depending on high oral transport efficiency based on their structural flexibility, gastrointestinal stability, biocompatibility, and/or intestinal epithelial affinity, nanovesicles can markedly augment the oral bioavailability of various poorly absorbed drugs. Vesicular drug delivery systems (VDDSs) demonstrate a lot of preferences and are becoming more prominent of late years in biomedical applications. Equally, these systems can potentiate a drug’s therapeutic index by ameliorating the oral absorption. This review devotes to comment on various VDDSs with special emphasis on the peroral drug delivery. The classification of nanovesicles, preparative processes, intestinal transport mechanisms, in vivo fate, and design rationale were expounded. Knowledge on vesicles-mediated oral drug delivery for bioavailability enhancement has been properly provided. It can be concluded that VDDSs with many merits will step into an energetic arena in oral drug delivery.

show abstract

Section: Optimizing Oral Bioavailability With Vesiclesmentioning

confidence: 99%

Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement

Ren¹,

Nie²,

Zhu³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Their particle sizes are generally within the range of 10-100 nm, which can improve the physicochemical properties and enhance the solubility and permeability of drugs [2,3]. Compared with traditional oral administration, nanoparticle delivery systems have unique advantages [4]: (1) they improve the stability and solubility of the drug in the gastrointestinal tract [5][6][7]; (2) they promote the penetration and adhesion of the drug in the mucus layer of the gastrointestinal tract, which is beneficial for the drug to reach intestinal epithelial cells [8][9][10][11]; (3) the controllable release of the drug can be achieved to maintain a stable blood drug concentration [12,13]; (4) by carrying out the surface modification of the nanoparticles, the drug can be targeted for delivery and can be released at the treatment site [14,15]; (5) they can change the absorption mechanism of the gastrointestinal tract and promote drug absorption [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Research Progress on the Mechanism of Nanoparticles Crossing the Intestinal Epithelial Cell Membrane

Cheng²,

Yang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Improving the stability of drugs in the gastrointestinal tract and their penetration ability in the mucosal layer by implementing a nanoparticle delivery strategy is currently a research focus in the pharmaceutical field. However, for most drugs, nanoparticles failed in enhancing their oral absorption on a large scale (4 folds or above), which hinders their clinical application. Recently, several researchers have proved that the intestinal epithelial cell membrane crossing behaviors of nanoparticles deeply influenced their oral absorption, and relevant reviews were rare. In this paper, we systematically review the behaviors of nanoparticles in the intestinal epithelial cell membrane and mainly focus on their intracellular mechanism. The three key complex intracellular processes of nanoparticles are described: uptake by intestinal epithelial cells on the apical side, intracellular transport and basal side exocytosis. We believe that this review will help scientists understand the in vivo performance of nanoparticles in the intestinal epithelial cell membrane and assist in the design of novel strategies for further improving the bioavailability of nanoparticles.

show abstract

Intranasal Delivery of Pure Nanodrug Loaded Liposomes for Alzheimer's Disease Treatment by Efficiently Regulating Microglial Polarization

Feng,

Zhang,

Zhao

et al. 2024

Small

View full text Add to dashboard Cite

The activated M1‐like microglia induced neuroinflammation is the critical pathogenic event in Alzheimer's disease (AD). Microglial polarization from pro‐inflammatory M1 toward anti‐inflammatory M2 phenotype is a promising strategy. To efficiently accomplish this, amyloid‐β (Aβ) aggregates as the culprit of M1 microglia activation should be uprooted. Interestingly, this study finds out that the self‐reassembly of curcumin molecules into carrier‐free curcumin nanoparticles (CNPs) exhibits multivalent binding with Aβ to achieve higher inhibitory effect on Aβ aggregation, compared to free curcumin with monovalent effect. Based on this, the CNPs loaded cardiolipin liposomes are developed for efficient microglial polarization. After intranasal administration, the liposomes decompose to release CNPs and cardiolipin in response to AD oxidative microenvironment. The CNPs inhibit Aβ aggregation and promote Aβ phagocytosis/clearance in microglia, removing roadblock to microglial polarization. Subsequently, CNPs are endocytosed by microglia and inhibit TLR4/NF‐κB pathway for microglia polarization (M1→M2). Meanwhile, cardiolipin is identified as signaling molecule to normalize microglial dysfunction to prevent pro‐inflammatory factors release. In AD transgenic mice, neuroinflammation, Aβ burden, and memory deficits are relieved after treatment. Through combined attack by extracellularly eradicating roadblock of Aβ aggregation and intracellularly inhibiting inflammation‐related pathways, this nanotechnology assisted delivery system polarizes microglia efficiently, providing a reliable strategy in AD treatment.

show abstract

Selenized liposomes with ameliorative stability that achieve sustained release of emodin but fail in bioavailability

Cited by 5 publications

References 26 publications

Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement

Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement

Research Progress on the Mechanism of Nanoparticles Crossing the Intestinal Epithelial Cell Membrane

Intranasal Delivery of Pure Nanodrug Loaded Liposomes for Alzheimer's Disease Treatment by Efficiently Regulating Microglial Polarization

Contact Info

Product

Resources

About